Scarica l'app Stockscreener
1.40
7.69%
0.10
Precedente Chiudi:
$1.30
Aprire:
$1.31
Volume 24 ore:
459.98K
Relative Volume:
0.26
Capitalizzazione di mercato:
$46.64M
Reddito:
$3.04M
Utile/perdita netta:
$-33.97M
Rapporto P/E:
-1.0145
EPS:
-1.38
Flusso di cassa netto:
$-52.47M
1 W Prestazione:
-15.66%
1M Prestazione:
-31.71%
6M Prestazione:
-65.00%
1 anno Prestazione:
-55.13%
Intervallo 1D:
$1.30
$1.415
Intervallo di 1 settimana:
$1.30
$1.72
Portata 52W:
$1.30
$8.75
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Nome
Rani Therapeutics Holdings Inc
Settore
Industria
Telefono
(408) 457-3700
Indirizzo
2051 RINGWOOD AVENUE, SAN JOSE
Confronta RANI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.40 | 46.64M | 3.04M | -33.97M | -52.47M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-06-14 | Iniziato | Maxim Group | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-07-27 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average PT from Brokerages - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.32 - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Kate Mckinley Acquires 17,960 Shares - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.85 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.85 - Investing.com India
Rani Therapeutics stock hits 52-week low at $1.94 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.94 - Investing.com India
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Target Price from Analysts - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $11.71 - MarketBeat
What is Zacks Small Cap’s Forecast for RANI FY2024 Earnings? - Defense World
What is Zacks Small Cap's Forecast for RANI FY2024 Earnings? - MarketBeat
RANI: Third Quarter Update - MSN
Rani Therapeutics' (RANI) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rani Therapeutics Advances in Biotherapeutics Market - TipRanks
Rani Therapeutics Holdings Inc (RANI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics Slashes Q3 Loss by 31%, Secures $20M Funding for GLP-1 Development | RANI Stock News - StockTitan
Rani Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) PT at $11.71 - Defense World
Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71 - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short Interest - MarketBeat
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch - Simply Wall St
RANI: New Triagonist Data in Weight Loss - Zacks Small Cap Research
Rani Therapeutics shares hold buy rating on positive preclinical data By Investing.com - Investing.com Australia
Rani Therapeutics stock gets positive outlook from H.C. Wainwright after novel obesity candidate progress - Investing.com Australia
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics shares hold buy rating on positive preclinical data - Investing.com
Rani Therapeutics (NASDAQ:RANI) Receives "Buy" Rating from HC Wainwright - MarketBeat
Rani Therapeutics reports promising obesity treatment delivery By Investing.com - Investing.com South Africa
Rani therapeutics sees $10 million in stock sales by major investors By Investing.com - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Sells 3,829,360 Shares - MarketBeat
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics reports promising obesity treatment delivery - Investing.com
Rani Therapeutics Announces New Preclinical Pharmacokinetic - GlobeNewswire
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - The Manila Times
Rani Therapeutics (RANI) Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - StreetInsider.com
Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering - MSN
Recent Insider Activity Could Benefit Comcast Corp (CMCSA) - Knox Daily
Market Momentum: Rani Therapeutics Holdings Inc (RANI) Registers a -33.33 Decrease, Closing at 2.12 - The Dwinnex
There is no doubt that Rani Therapeutics Holdings Inc (RANI) ticks all the boxes. - SETE News
An Analysis of Avidity Biosciences Inc (RNA)’s Potential Price Growth - Knox Daily
Form 424B5 Rani Therapeutics Holdin - StreetInsider.com
Rani Therapeutics Holdings Inc Azioni (RANI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rani Therapeutics Holdings Inc Azioni (RANI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Imran Talat | Chief Executive Officer |
Dec 09 '24 |
Buy |
1.94 |
10,296 |
19,974 |
494,751 |
| South Cone Investments Limited | 10% Owner |
Oct 15 '24 |
Sale |
2.65 |
3,829,360 |
10,141,674 |
8,302,194 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):